Mary Norine Walsh, MD, MACC

CHICAGO — An autologous point-of-care cell therapy for adults with ischemic HF with reduced ejection fraction was safe and may be beneficial for select candidates, though a pivotal study did not meet its primary efficacy outcome.

PHILADELPHIA — Patients with HF with reduced ejection fraction who were provided information about out-of-pocket costs for medications were more likely to discuss costs with their doctors than those who were not, researchers reported.

PHILADELPHIA — In patients with advanced HF and a fully magnetically levitated left ventricular assist device, avoiding aspirin was safe and reduced bleeding, researchers reported at the American Heart Association Scientific Sessions.

NATIONAL HARBOR, Md. — Aficamten was associated with sustained improvement in patient-reported symptom burden and quality of life at 6 months when used to treat obstructive hypertrophic cardiomyopathy, a speaker reported.